TENOFOVIR HETERO tenofovir disoproxil fumarate 300mg tablets blister

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

tenofovir disoproxil fumarate, Quantity: 300 mg

Pieejams no:

Hetero Australia Pty Ltd

Zāļu forma:

Tablet

Kompozīcija:

Excipient Ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; lactose monohydrate; pregelatinised maize starch; titanium dioxide; hypromellose; triacetin

Ievadīšanas:

Oral

Vienības iepakojumā:

60's, 30's

Receptes veids:

(S4) Prescription Only Medicine

Ārstēšanas norādes:

TENOFOVIR HETERO in combination with other antiretroviral agents is indicated for the treatment of HIV-infected adults and paediatric patients 12 years of age and older.,TENOFOVIR HETERO is indicated for the treatment of chronic hepatitis B in adults (see CLINICAL TRIALS).,TENOFOVIR HETERO is indicated for the treatment of chronic hepatitis B in paediatric patients 12 years of age and older with compensated liver disease and with evidence of immune active disease, i.e, active viral replication, persistently elevated serum ALT levels or evidence of active inflammation.

Produktu pārskats:

Visual Identification: White coloured, almond shaped, film-coated tablets debossed with 'H' on one side and '123' on the other side; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Autorizācija statuss:

Registered

Autorizācija datums:

2018-12-06